Clinical Trials

40 enrolled

Multiple Myeloma

NCT00092222 2026-04-14

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

75 enrolled

Multi-centric Castleman's Disease, Macular dystrophy, corneal type 1, Lymphadenopathy, Lymphoproliferative Disorders, Neoplasms, HIV Infections

NCT04133636 2026-04-13

CARTITUDE-2

210 enrolled

Multiple Myeloma

NCT06169215 2026-04-13

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

70 enrolled

Multiple Myeloma

NCT06577025 2026-04-13

aMMbition

43 enrolled

Multiple Myeloma

NCT04268498 2026-03-24

ADVANCE

310 enrolled

Multiple Myeloma

NCT06353022 2026-03-17

IFm2022-01

103 enrolled

Multiple Myeloma

NCT00492050 2026-03-11

Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia

46 enrolled 10 charts

Waldenstrom Macroglobulinemia

NCT04151667 2026-03-11

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

33 enrolled 11 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04802356 2026-03-05

Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

50 enrolled

Multiple Myeloma

NCT03589222 2026-02-27

SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

62 enrolled

Multiple Myeloma

NCT02718833 2026-01-22

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

52 enrolled

Multiple Myeloma, Recurrence

NCT04653246 2025-12-23

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

52 enrolled

Multiple Myeloma

NCT03620903 2025-12-05

Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia

53 enrolled

Waldenstrom Macroglobulinemia

NCT03004287 2025-09-10

2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

50 enrolled

Multiple Myeloma

NCT03314181 2025-08-14

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

156 enrolled

Multiple Myeloma, Neoplasms

NCT04052880 2025-07-20

Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

17 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05123131 2025-07-08

Isa-RVD

54 enrolled

Multiple Myeloma

NCT04775550 2025-07-02

PRISM

61 enrolled

Multiple Myeloma

NCT00871013 2025-07-01

Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy

160 enrolled

Neoplasms, Plasma Cell

NCT00869232 2025-06-29

UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

90 enrolled

Multiple Myeloma

NCT04166565 2025-04-17

EMN19

41 enrolled

Multiple Myeloma

NCT01415752 2025-04-08

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

373 enrolled 14 charts

Lymphoma, Lymphoma, Mantle-Cell

NCT04717700 2025-03-18

SABLe

50 enrolled

Multiple Myeloma

NCT06853080 2025-02-28

Feasibility of Using Bortezomib With or Without Chemotherapy in Patients With Atypical Teratoid/Rhabdoid Tumors

6 enrolled

Neoplasms, Rhabdoid Tumor

NCT04140162 2024-10-09

Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy

57 enrolled

Multiple Myeloma

NCT03942224 2024-06-21

DeRIVE

49 enrolled

Multiple Myeloma

NCT03188172 2024-05-14

MUKnineb

95 enrolled